Does Cosentyx Raise Heart Risks?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries warnings for major adverse cardiovascular events (MACE) like heart attack, stroke, and cardiovascular death. This stems from pooled trial data showing higher MACE rates in patients with cardiovascular risk factors, though no definitive causation is established.[1][2] The label advises assessing heart risk before starting and monitoring patients with history of heart disease.
Who Might Face Higher Heart Risks on Cosentyx?
Patients over 50 with coronary artery disease, high cholesterol, hypertension, diabetes, or smoking history saw MACE rates of 1.3% versus 0.7% in placebo groups across trials.[2] Real-world data from registries like CorEvitas show no overall increased heart events compared to other biologics, but subgroup risks persist.[3] Avoid if active serious infection or recent live vaccines; heart concerns amplify with these comorbidities.
How Does Cosentyx Compare to Other Biologics for Heart Safety?
Unlike TNF inhibitors (e.g., Humira, Enbrel), which sometimes link to heart failure worsening, Cosentyx's IL-17 mechanism may offer neutral or protective effects in some psoriasis studies by reducing vascular inflammation.[4] Head-to-head trials with ixekizumab (Taltz) show similar cardiovascular profiles.[5] Methotrexate or apremilast often serve as lower-risk alternatives for mild cases.
| Drug | Key Heart Concern | MACE Risk in Trials |
|------|-------------------|---------------------|
| Cosentyx | Warning in high-risk patients | 1.3% (vs 0.7% placebo) [2] |
| Humira | Heart failure exacerbation | Black box warning [6] |
| Taltz | Similar to Cosentyx | Comparable rates [5] |
| Stelara | Fewer CV signals | Lower reported MACE [4] |
What Do Guidelines Say About Starting Cosentyx?
ACR and EULAR guidelines recommend cardiovascular risk screening before IL-17 inhibitors but do not contraindicate in stable heart patients.[7] FDA requires a patient registry for long-term monitoring. No patent issues affect availability—Cosentyx's key patents expire around 2032.[8]
When to Talk to Your Doctor Before Using Cosentyx
Consult if you have heart disease, stents, or recent events; they may prefer statins, lifestyle changes, or alternatives first. Track symptoms like chest pain. No evidence supports blanket avoidance, but personalized risk-benefit applies—e.g., psoriasis severity versus heart profile.
Sources
[1]: FDA Cosentyx Label
[2]: Novartis Safety Data
[3]: CorEvitas Psoriasis Registry
[4]: JAMA Dermatology Review
[5]: Lancet Rheumatology
[6]: FDA Humira Label
[7]: ACR Guidelines
[8]: DrugPatentWatch: Cosentyx